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Abstract
Mutations in the retinitis pigmentosa 1 (RP1) gene are a common cause of autosomal dominant retinitis pigmentosa (adRP),
and have also been found to cause autosomal recessive RP (arRP) in a few families. The 33 dominant mutations and 6
recessive RP1mutations identified to date are all nonsense or frameshift mutations, and almost exclusively (38 out of 39) are
located in the 4th and final exon of RP1. To better understand the underlying disease mechanisms of and help develop
therapeutic strategies for RP1 disease, we performed a series of human genetic and animal studies using gene targeted and
transgenic mice. Here we report that a frameshift mutation in the 3rd exon of RP1 (c.686delC; p.P229QfsX35) found in a
patient with recessive RP1 disease causes RP in the homozygous state, whereas the heterozygous carriers are unaffected,
confirming that haploinsufficiency is not the causative mechanism for RP1 disease. We then generated Rp1 knock-in mice
with a nonsense Q662X mutation in exon 4, as well as Rp1 transgenic mice carrying a wild-type BAC Rp1 transgene. The Rp1-
Q662X allele produces a truncated Rp1 protein, and homozygous Rp1-Q662X mice experience a progressive photoreceptor
degeneration characterized disorganization of photoreceptor outer segments. This phenotype could be prevented by
expression of a normal amount of Rp1 protein from the BAC transgene without removal of the mutant Rp1-Q662X protein.
Over-expression of Rp1 protein in additional BAC Rp1 transgenic lines resulted in retinal degeneration. These findings
suggest that the truncated Rp1-Q662X protein does not exert a toxic gain-of-function effect. These results also imply that in
principle gene augmentation therapy could be beneficial for both recessive and dominant RP1 patients, but the levels of
RP1 protein delivered for therapy will have to be carefully controlled.
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Introduction
Recent reports of the success of Phase I clinical trials of gene
therapy for Leber congenital amaurosis (LCA) and X-linked
adrenoleukodystrophy (ALD) indicate that we are entering an era
of genetic therapies, at least for some forms of genetic disease [1–
8]. Since these initial successes are based on gene augmentation
therapy, it has become increasingly important to determine the
mechanisms by which mutations identified to cause inherited
disorders such as LCA and retinitis pigmentosa (RP) exert their
pathologic effects. Mutations can cause disease via a protein’s loss-
of-function, gain-of-function or dominant-negative activity [9,10].
Disease caused by loss-of-function or dominant-negative muta-
tions, in which the mutant protein competes with the wild-type
protein and blocks its full function, are potentially amenable to
treatment with gene augmentation therapy. In contrast, treatment
of dominant disorders in which the mutant protein acquires a
novel toxic function (gain-of-function mutations) will require
removal or suppression of the mutant allele [9,10]. Despite the
importance of distinguishing between different function of
mutations, mechanisms have been determined for only a limited
number of dominantly inherited disorders [11]. This is especially
true for inherited retinal degenerations (IRDs), one of the most
genetically diverse group of inherited disorders [12]. IRDs result in
blindness by causing dysfunction and ultimately death of the rod
and cone photoreceptor cells of the retina [13,14]. Since the first
IRD genes, rhodopsin (RHO) and CHM, were discovered two
decades ago [15,16], over 180 disease genes have been identified,
which account for approximately 50–60% of the genetic causes of
disease in IRD patients [17–19]. Retinitis pigmentosa (RP) is the
most common form of IRD, affecting 1:1000 to 1:4000 people
worldwide [18,20]. It is characterized by nyctalopia and visual
field loss, followed by loss of central vision, eventually leading to
blindness.
Mutations in the RP1 gene are the second most common cause
of autosomal dominant RP (adRP; 5.5%), and have also been
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found to cause autosomal recessive RP (arRP) [21–34]. Studies to
date have shown that the RP1 protein (2156 aa, 240 kDa) is part
of the axoneme of photoreceptor sensory cilia (PSC; also called
outer segments) [35]. It is a photoreceptor-specific microtubule-
associated protein (MAP) that is required for normal organization
of membrane discs in the light-sensitive PSC of rod and cone cells.
Microtubule binding domains in the N-terminal portion of RP1
mediate its interaction with the axoneme, and the C-terminal
portion of the protein is hypothesized to interact with other
proteins to help mediate the organization of outer segment discs
[36–38]. To date, 33 mutations in RP1 have been identified to
cause adRP (Figure 1A). These are all nonsense or frameshift
mutations clustered at the beginning of the 4th and final exon of
RP1 (Figure 1A) [21–33]. Compared to the autosomal dominant
form, only a small number of families with arRP due to mutations
in RP1 have been reported, including 4 homozygous mutations
(c.1606insTGAA, c.2847delT, c.4703delA, and c.5400delA) and
one pair of compound heterozygous mutations (c.5_6delGT and
c.4941_4942insT) (Figure 1A)[34,39–41]. These are also frame-
shift mutations, with 5 out of 6 located in the final exon as well.
Since nonsense-mediated decay (NMD) is thought not to occur if
the nonsense mutation is in the last exon, all those dominant and
recessive mutations in the last exon of RP1 are expected to
produce stable transcripts, resulting in the production of truncated
RP1 proteins that lack the C-terminal 1/3 rd to 2/3 rds of the full
length RP1 protein in the photoreceptor cells of RP patients. Our
previous studies on lymphoblasts of patients with RP1 disease and
gene targeted Rp1-tm1EAP mice suggest that the mutant RP1
mRNAs with nonsense mutations in exon 4 are expected to escape
NMD, but the hypothesis that premature termination codons in
exon 4 lead to the production of truncated Rp1 proteins in vivo has
not been tested empirically with a representative mutant allele
[37].
To elucidate the molecular mechanisms of RP1 mutations so
that therapeutic strategies can be developed for RP1 disease, we
performed human genetic studies and experiments using several
lines of Rp1 gene targeted and transgenic mice. First, we evaluated
the family of an adult patient with recessive RP due to a
homozygous mutation in exon 3 of RP1, which is predicted to be
null. The sibling and parents of this patient, who all carry a single
mutant RP1 allele, do not exhibit evidence of RP, confirming that
functional hemizygosity of RP1 does not cause disease [41]. Next,
we generated and characterized Rp1 knock-in mice with a Q662X
nonsense point mutation in exon 4 of human RP1. As predicted,
the mutant Rp1-Q662X allele produces a truncated Rp1 protein,
and homozygous Rp1-Q662X experience photoreceptor degener-
ation. Third, we generated and characterized transgenic mice that
produce a tagged version of the full-length Rp1 protein.
Expression of normal levels of Rp1 protein from the transgene is
well tolerated, but lines of transgenic mice that over-express the
Rp1 protein experience retinal degeneration. Fourth, expression of
wild-type Rp1 protein in homozygous Rp1-Q662X mice prevent-
ed photoreceptor degeneration. These results indicate that the
truncated Rp1-Q662X protein does not exert a toxic gain-of-
function effect in the retina, suggesting that dominant mutations in
RP1 do not cause disease via a gain-of-function mechanism.
Results
Haploinsufficiency of RP1 does not Cause Retinal
Degeneration in Humans
As part of a large study to identify the genetic causes of RP in
The Netherlands via homozygosity mapping [42], we found the
disease-causing mutation for a Dutch patient with RP (Figure 1B–
E). In this patient, whole-genome homozygosity mapping revealed
a significant homozygous region of 8.3 Mb on chromosome 8,
between rs1394468 and rs936616, in which the RP1 gene resides.
Mutation analysis of RP1 in this patient revealed the homozygous
1-bp deletion in exon 3 (c.686delC) that is predicted to result in a
frame-shift and premature termination of the protein
(p.P229QfsX35; Figure 1A, E). Mutation analysis in the unaffected
parents and sister of the patient revealed that these three
individuals carried the mutation heterozygously (Figure 1B). This
is the first mutation reported to date that causes arRP in the
homozygous state, but is not located in the final exon.
The proband in this family (individual II-1, Figure 1) experi-
enced nyctalopia from early childhood, and was diagnosed with
RP at age 13. At that time, visual acuity was 0.6 in the right eye
and 0.5 in the left eye, and electroretinogram (ERG) recordings
were severely reduced with a rod-cone pattern. On recent
examination at age 30, visual acuity was light perception in both
eyes. The ERG was non-recordable (Figure 1C). Ophthalmoscopy
revealed moderate pallor of the optic discs and attenuation of the
retinal blood vessels (Figure 1D). The retinal pigment epithelium
(RPE) in the posterior pole was relatively preserved, with subfoveal
atrophy. Bone spicule pigmentation and RPE atrophy were
observed in the retinal peripheries. In contrast, examination of the
heterozygous parents (ages 60 and 57 respectively) and sister (age
28) did not reveal any abnormalities. None of these family
members had nyctalopia, and ERG recordings showed normal
retinal function for both parents (Figure 1C).
The observation that carriers of the c.686delC mutation do not
have RP is consistent with a recent report describing a patient with
arRP due to compound heterozygous frameshift mutations in RP1,
c.5_6delGT (p.S2RfsX16, exon 2) and c.4941_4942insT
(p.P1648SfsX13, exon 4). In that family, the carrier of the
p.S2RfsX16 allele, which creates a premature termination codon
in exon 2, did not show evidence of RP either [41]. Since the
nonsense mutations, c.5_6delGT (p.S2RfsX16, exon 2) and
c.686delC (p.P229QfsX35, exon 3), occur in the 2nd or 3rd rather
than the final exon in these two families, they are expected to lead
to NMD of the mutant mRNAs, and thus create null alleles [43].
These findings from two recessive RP1 families suggest that
haploinsufficiency of RP1 does not cause retinal degeneration in
humans.
Generation and Characterization of Rp1-Q662X Knock-in
Mice
We next focused on determining the possible disease mecha-
nism for mutations identified in the final exon of human RP1. We
hypothesized that RP1 transcripts with stop mutations in the 4th
exon can escape NMD and produce truncated proteins, as
predicted from previous studies [37]. To empirically address this
question, we generated knock-in mice with a Q662X nonsense
point mutation in the Rp1 gene to represent those mutations that
create premature termination codons in exon 4 of human RP1
[21–33]. The Rp1-Q662X targeting vector was generated from a
mouse bacterial artificial chromosome (BAC) clone by introducing
the Q662X mutation along with a Frt-flanked neomycin selection
cassette into the mouse Rp1 gene using recombination-based gene-
targeting techniques (Figure 2A) [44,45]. The neomycin selection
cassette was then removed by crossing F1 Rp1-Q662X-Neo mice
with universal FLPe deleter mice to generate the final excised
targeted Rp1-Q662X knock-in allele (ki) (Figure 2A) [46].
Intercrosses of heterozygous Rp1+/Q662X mice generated the
expected number of wild-type, Rp1+/Q662X and Rp1Q662X/Q662X
mice. The mutant mice are fertile, have normal weights and a
normal lifespan.
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Figure 1. RP1 Gene, Clinical and Sequence Data for Family W04-348. A. RP1 gene and identified mutations. The gene structure of RP1 is
depicted, with the locations of mutations that cause adRP and arRP indicated; the mutations above the RP1 gene structure cause dominant RP,
labeled as adRP in red; whereas mutations below the RP1 gene structure cause recessive RP, labeled as arRP in blue; frameshift mutation
p.P229QfsX35 reported to cause arRP in this study is in bold. The portion of the gene that encodes that DCX domains is also indicated. The arrow on
the top indicates the location of the R677X (human) and Q662X (mouse) mutations. B. Pedigree for family W04-348. The c.686delC, p.P229QfsX35
mutation is designated by M. C. ERG traces from a normal control, the patient’s parents (I-1, I-2 (age 57), and the affected patient (II-1). The five
standard ISCEV recordings are shown, from the top including: scotopic rod responses, scotopic combined rod-cone responses, oscillatory potentials,
photopic single flash and photopic 30Hz responses. The amplitude and time scales are indicated. The ERG responses of the patient’s parents show
normal amplitudes and implicit times; the patient had no recordable rod or cone responses. The deflections shown in the 30 Hz recordings for the
patient are due to motion artifact. The thicker traces are from the right eye, the thinner from the left eye. D. Fundus photos (left) and fundus
autofluorescence images (right) of the affected patient II-1(age 30) and his father I-1 (age 60). The patient has typical findings of RP, with optic disc
pallor, attenuation of the retinal blood vessels, RPE atrophy and bone spicule pigmentation outside the macula. As shown in the autofluorescence
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To determine if the mutant Rp1-Q662X mRNA is spliced
correctly and produces a truncated protein in photoreceptor cells,
retinas from 4-week-old Rp1+/+, Rp1+/Q662X, and Rp1Q662X/Q662X
mice were evaluated using RT-PCR, Western blot and immuno-
fluorescence analyses. The RT-PCR results showed that mutant
Rp1-Q662X allele was correctly spliced (Figure 2E). To distinguish
between the wild-type Rp1 and mutant Rp1-Q662X protein, we
used two anti-Rp1 antibodies: anti-N-Rp1 and anti-C-Rp1, which
image, the RPE in the macular region is relatively preserved. In contrast, the father’s fundi are normal. E. Sequence traces showing the homozygous
c.686delC mutation in patient II-1, carrier status of this mutation in the patient’s father I-1, and the wild-type sequence in an unaffected Dutch
control. Note that the sequence trace of the mutant allele in individual I-1 is shifted slightly.
doi:10.1371/journal.pone.0043251.g001
Figure 2. Generation and Characterization of Rp1Q662X/Q662X Knock-in Mice. A. Gene targeting strategy to introduce Q662X mutation into
the endogenous Rp1 locus. The gene targeting vector was produced by introducing the Neo-Zeo selection cassette and Q662X mutation into the Rp1
gene in a BAC which contains 140 kb of mouse genomic DNA including the Rp1 locus, using homologous recombination techniques. The gene
targeting vector was then retrieved from the modified BAC, and used to transfect mouse ES cells. Correctly targeted ES cells were injected into
blastocysts to generate Rp1-Neo-Q662X mice. Crosses to Flpe deleter mice were used to remove the Frt-flanked Neo-Zeo selection cassette and
generate the final Rp1-Q662X allele. B, BamHI restriction sites; P, PmeI restriction sites. B. Southern blots using the 59 and 39 probes indicated in A
demonstrating correct targeting of the Rp1 locus in mouse ES cells. The 12.6 and 18 kb bands in the 59 and 39 blots, respectively, indicate correct
recombination to generate the Rp1-Neo-Q662X allele. The large size of the wild-type Pme1 restriction fragment (60 kb) in the 39 blot makes it difficult
to resolve this band with standard electrophoresis techniques. C. Sequence traces from PCR products amplified from wild-type, heterozygous (wt/ki)
and homozygous (ki/ki) mice. D. Example PCR-based genotyping of Rp1-Q662X (ki) knock-in mice. Using PCR primers that amplify across the residual
Frt-LoxP sites, the wild-type and ki alleles can be readily distinguished. E. RT-PCR of retinal RNA from mice of indicated genotypes showing the
correct splicing of mutant Rp1-Q662X allele as that of wild type Rp1 allele, using primer sets bridging exon 2 to 3 and exon 3 to 4. F. Predicted
proteins produced by the wild-type (wt) and knock-in (ki) Rp1 alleles, showing locations of the anti-N-Rp1 and anti-C-Rp1 antibodies used in panels G
and H. G. Western blot of retinal extracts from mice of the indicated genotypes showing production of the 74 kD truncated protein by the knock-in
(ki) allele. Note that there is no full-length Rp1 protein detected in the retinas of the homozygous ki/ki mice by either the anti-N-Rp1 or anti-C-Rp1
antibodies. H. Immunofluorescence analysis of Rp1 proteins (red) produced in the retinas of wild-type (wt/wt) vs. homozygous knock-in (ki/ki) mice
using the anti-N-Rp1 and anti-C-Rp1 antibodies indicated in panel E. Note that the truncated Rp1 protein produced in the retinas of the ki/ki mice
locates correctly to the axonemes of PSC, just like the full-length protein in the wt/wt retinas. Note also the lack of full-length Rp1 protein production
in the retinas of the ki/ki mice (AX, axoneme; IS, inner segment; ONL, outer nuclear layer; OS, outer segment).
doi:10.1371/journal.pone.0043251.g002
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recognize the N-terminal portion and C-terminal portion of Rp1
respectively (Figure 2F) [35,38]. As expected, a 240 kDa wild-type
Rp1 protein was detected in the retinas from wild-type and
heterozygous mice by anti-C-Rp1 and anti-N-Rp1 antibodies
(Figure 2G). No full length Rp1 protein could be detected in the
homozygous Rp1Q662X/Q662X mice by anti-C-Rp1 or anti-N-Rp1
antibodies. The levels of the normal Rp1 protein in heterozygous
mice were approximately half of that detected in the wild-type
mice. Probing with anti-N-Rp1 antibody revealed that a ,74 kDa
truncated protein was expressed in the heterozygous and
homozygous mutant mice (Figure 2G). Interestingly, the truncated
Rp1-Q662X protein was localized to the axoneme of PSCs using
the anti-N-Rp1 antibody, which is identical to the location of the
wild-type Rp1 protein detected by both anti-N-Rp1 and anti-C-
Rp1 antibodies (Figure 2H).
The retinal morphology and function of the mutant Rp1 knock-in
mice and their littermate controls were evaluated at indicated time
points (Figure 3). Mice homozygous for the Rp1-Q662X allele
experienced progressive retinal degeneration. At 1 month of age, the
outer nuclear layer (ONL) of retinas from the Rp1Q662X/Q662X mice
was two to three rows of nuclei thinner than that in wild-type controls.
By 6 month of age, only 3–4 rows of photoreceptor nuclei remained
in the Rp1Q662X/Q662X mice (Figure 3A). Photoreceptor cell loss was
completed by 12 month of age (data not shown). Ultrastructural
analyses revealed grossly abnormal outer segments in homozygous
Rp1Q662X/Q662X mice. At 10 days of age, small packets of enlarged
discs replaced the normal organized stacks of discs observed in
control animals (Figure 3B). These changes were even more evident
at 1 month of age, and recapitulate the phenotype observed in mice
with other mutant Rp1 alleles (Figure 3C) [36,37]. Consistent with the
structural abnormalities, the Rp1Q662X/Q662X mice demonstrated
progressive degeneration of photoreceptor function. ERG analysis at
1 month of age showed the rod a-wave reduced by ,50% in
Rp1Q662X/Q662X mice compared to littermate controls (Figure 3D).
By 6 months of age, all measures of rod and cone function were
decreased in the Rp1Q662X/Q662X mice (Figure 3E). At 30 months of
age, no recordable ERG responses were detected (Figure 3F). Mice
heterozygous for the Rp1-Q662X allele did not show significant
retinal structural or functional abnormality up to 30 months of age,
consistent with results of our prior studies of the Rp1-tm1EAP mice
which showed that truncated Rp1 proteins produce dominant disease
on an albino background, but not a pigmented background [47]
(Figure 3D, E, F).
Generation and Characterization of Rp1 Transgenic Mice
Expression of correctly localized truncated Rp1 protein in the
retinas of the Rp1-Q662X mice raised the possibility that the
truncated protein could have acquired an altered function, which
disrupts the normal function of wild-type Rp1, and causes disease
via a gain-of-function mechanism. However, the lack of retinal
phenotype in the Rp1+/Q662X heterozygous mice on the mixed
129Sv/C57BL6 genetic background used in the present studies
did not allow us to formally distinguish between different disease
mechanisms in heterozygous mice. As an alternative approach to
address this question, we generated transgenic mice that express
epitope-tagged versions of the full-length Rp1 protein, and then
transferred the wild-type Rp1 transgene onto the Rp1Q662X/Q662X
background to study the interaction of mutant and wild-type Rp1
protein, and determine if the addition of wild-type Rp1 protein
can modulate the phenotype in Rp1Q662X/Q662X mutant mice. For
these studies, we placed the SF-TAP (Strep-tag II - FLAG) and
LAP (EGFP - S-tag) tags at the N-terminus of the Rp1 coding
sequence in a BAC that contains 140 kb of genomic DNA
surrounding Rp1 (Figure 4A) [48,49]. Three lines of N-SF-TAP-
Rp1 transgenic mice (designated T1–T3) and three lines of N-LAP-
Rp1 transgenic mice (designated L1–L3) were produced following
microinjection of each BAC into oocytes [50]. When backcrossed
with C57BL/6J mice, all six founders passed the N-SF-TAP-Rp1
or N-LAP-Rp1 transgenes to approximately half of their offspring.
To determine the expression level and location of the tagged
Rp1 proteins produced by the N-SF-TAP-Rp1 and N-LAP-Rp1
transgenes, retinas from 2-month-old T1–T3 and L1–L3 trans-
genic lines were evaluated using Western blot and immunofluo-
rescence analyses (Figure 4B–4E). In the N-SF-TAP-Rp1 trans-
genic lines, the N-SF-TAP-Rp1 protein was expressed at a normal
level in line T1, but over-expressed in lines T2 and T3 (Figure 4B).
The total level of Rp1 protein in line T1 was 144% of that
observed in non-transgenic littermate controls, indicating that the
transgene increased expression approximately 44%, or nearly the
amount expected from a third Rp1 allele (Figure 4B). The N-SF-
TAP-Rp1 transgene in line T2 increased the total Rp1 protein
level to ,300% of normal. The total level of Rp1 protein in line
T3 was only slightly elevated, but the retinas in these mice were
also significantly degenerated, with 40% of the photoreceptor
nuclei remaining in the outer nuclear layer. Providing that the
expression level of tagged Rp1 proteins are proportionate to the
thickness of the outer nuclear layer of photoreceptor nuclei, the N-
SF-TAP-Rp1 protein level in line T3 is about 2–3 fold greater
than wild-type (Figure 4B, D). The higher expression level of
tagged RP1 in line T3 was also evidenced by the signal intensity of
Rp1 immunostaining in the retinal sections (Figure 4D). Immu-
nofluorescence analyses using anti-Rp1 antibody to detect the total
Rp1 protein and anti-flag antibody to detect the SF-TAP tagged
Rp1 protein showed that the N-SF-TAP-Rp1 protein in line T1
co-localizes with the wild-type protein in the PSC axoneme
(Figure 4D). There is also some N-SF-TAP-Rp1 signal in the
synaptic region of photoreceptor cells that is not present in wild-
type retinas. The over-expressed N-SF-TAP-Rp1 proteins in line
T2 and T3 localized correctly to PSC axonemes, but also mis-
localized to photoreceptor inner segments and synaptic region,
especially in the line T3 retinas (Figure 4D).
In the N-LAP-Rp1 transgenic lines L1–L3, the N-LAP-Rp1
protein was expressed at normal levels in lines L1 and L2, but
over-expressed in line L3 (Figure 4C). For all lines, the N-LAP-
Rp1 protein co-localized in the PSC axoneme with the wild-type
Rp1 protein. As for the N-SF-TAP-Rp1 protein, there is also some
N-LAP-Rp1 signal in the synaptic region of photoreceptor cells
that is not present in wild-type retinas. In addition, there were
EGFP signals in the inner segments and cell bodies of the
photoreceptors (Figure 4E). Since this was not detected by the anti-
Rp1 antibodies, it may be due to truncated versions of the N-LAP-
Rp1 protein that retain the N-terminal EGFP tag, but have lost
the C-terminal antibody binding domain. The N-LAP-Rp1
transgene expression in line L2 is not completely uniform, with
a mixture of cells that do and do not express the transgene. As for
the T3 line, there is also photoreceptor degeneration in the L3
line, with fewer photoreceptor nuclei remaining in the outer
nuclear layer.
To further evaluate the long-term effects of different levels of
additional wild-type Rp1 protein on retinal function, detailed
retinal histologic and functional analyses were performed in these
transgenic lines at 1 year of age (Figure 5). Results showed that the
histology of photoreceptors in lines T1, L1 and L2 are well
preserved in mice up to 1 year of age (Figure 5A). In contrast, lines
T2, T3 and L3 that over-express the tagged transgenes showed
photoreceptor degeneration at 1 year of age, with shortened PSCs
and loss of photoreceptor nuclei. Ultrastructural analyses of Line
T1 and L2 confirmed normal PSC structure in these two lines of
Prevention of Rp1-Related Retinal Degeneration
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transgenic mice (Figure 5B). Consistent with the normal histology,
ERG analysis showed that line T1 and L2 mice have normal
retinal function at 1 year of age (Figure 5C). All together, these
data suggest the N-SF-TAP-Rp1 and N-LAP-Rp1 proteins
localize correctly to the PSC axonemes and function normally,
but also indicate that over-expression of the transgene is associated
with mislocalization of the tagged proteins and can lead to
photoreceptor degeneration.
Figure 3. Retinal degeneration phenotype in the Rp1-Q662X mice. A. Light microscopic images of semi-thin sections of retinas from wild-
type (wt/wt) and homozygous Rp1-Q662X knock-in mice (ki/ki) of the ages indicated. Note that thinning of the outer nuclear layer in the ki/ki mice is
evident at 1 month, and progresses so that by 6 months of age only 2–3 rows of photoreceptor nuclei remain. Note also the disorganization and
shortening of the photoreceptor outer segments in the ki/ki mice. (GCL, ganglion cell layer; INL, inner nuclear layer; IPL, inner plexiform layer; IS, inner
segment; ONL, outer nuclear layer; OPL, outer plexiform layer; OS, outer segment; RPE, retinal pigment epithelium; 4006magnification for all images).
B, C. Electron micrographs of retinas from wt/wt and ki/ki mice at 10 days (B) and 1 month of age (C). At 10 days of age small packets of enlarged disc
membranes parallel to the axis of the axonemes replaced the normal perpendicularly orientated stacks of discs observed in control animals. These
defects of outer segments were even more evident at 1 month of age, with disorganized membranous whirls in place of outer segments, compared
to the well aligned, uniform discs in the control retina (IS, inner segments; OS, outer segments; RPE, retinal pigment epithelium; bars = 2 mm). D–F.
Average rod and cone ERG amplitudes for wild-type (wt/wt), heterozygous (wt/ki) and homozygous (ki/ki) Rp1-Q662X knock-in mice. The amplitudes
+ SD are shown for mice of the three genotypes at 1 month (D), 6 months (E) and 30 months of age (F). Significant differences (P,0.05) indicated by
*. Note that the rod-a waves of the ki/ki mice were significantly decreased at 1 month of age. By 6 months of age, all measures of rod and cone
function were decreased in the ki/ki mice. By 30 months of age, no recordable ERG responses were detected.
doi:10.1371/journal.pone.0043251.g003
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Figure 4. Expression of N-SF-TAP-Rp1 and N-LAP-Rp1 Transgenes. A. Diagram of Rp1 gene, N-SF-TAP-Rp1 and N-LAP-Rp1 transgenes. The
TAP and LAP tags were introduced into the beginning of the Rp1 coding sequence in exon 2 in BAC 314, which contains 140 kb of mouse genomic
DNA surrounding the Rp1 locus. B-C. Western blot analyses of Rp1 proteins in N-SF-TAP-Rp1 and N-LAP-Rp1 mice. Equal amounts of protein from
retinal extracts of wild-type, N-SF-TAP-Rp1 and N-LAP-Rp1 mice were analyzed by Western blotting using anti-Rp1 antibodies. The blots were also
probed with antibodies to ATPase as a loading control. The Rp1 levels for the different transgenic lines were quantified and normalized to the ATPase
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Expression of Additional Full-length Rp1 Protein can
Delay Photoreceptor Degeneration in Rp1Q662X/Q662X
Mice
The classic method to distinguish between dominant-negative
and gain-of-function mechanisms of a dominant mutation is to
evaluate the effect of different ratios of wild-type to mutant protein
on modulating the phenotype [9,10]. This can be achieved by
creating transgenic mice expressing either a mutant allele on a wild-
type background, or a wild-type allele on a mutant background. In
this study, we transferred the wild-type N-SF-TAP-Rp1 or N-LAP-
Rp1 transgenes onto the homozygous Rp1-Q662X background to
generate new transgenic lines. Animals carrying twomutant Q662X
alleles at the endogenous Rp1 locus and a tagged Rp1 transgene were
designated as Rp1Q662X/Q662X : N-SF-TAP-Rp1 or Rp1Q662X/Q662X
: N-LAP-Rp1mice. We used lines T1 and L2 for these experiments,
signals. B. N-SF-TAP-Rp1mice. The total level of Rp1 protein in line T1 was 144% of that observed in non-transgenic littermate controls, indicating that
the transgene increased expression approximately 44%, or nearly the amount expected from a third Rp1 allele. The N-SF-TAP-Rp1 transgene in line T2
is over-expressed relative to the wild-type protein, as it increased the total Rp1 protein level to,300% of normal. The total level of Rp1 protein in line
T3 was only slightly elevated, but the retinas in these mice were also significantly degenerated, with 40% of the photoreceptor nuclei remaining in
the outer nuclear layer, suggesting that the N-SF-TAP-Rp1 protein in this transgenic line is also 2–3 fold greater than wild-type. C. N-LAP-Rp1 mice.
The levels of N-LAP-Rp1 fusion protein in lines L1 and L2 mice were approximately half of that observed for the wild-type Rp1 protein, again
indicating that the transgene increased expression approximately the amount expected from a third Rp1 allele. In contrast, N-LAP-Rp1 transgene in
line L3 is over-expressed, and increased the total Rp1 protein level to ,250% of normal. D. Immunofluorescence analyses of wild-type Rp1 protein
(anti-Rp1 antibodies; red) and N-SF-TAP-Rp1 protein (anti-FLAG antibodies; green) in three N-SF-TAP-Rp1 transgenic lines and wild-type littermate
control. Note that the wild-type Rp1 protein is located in the axoneme of photoreceptor outer segments. The N-SF-TAP-Rp1 protein in transgene line
T1 shares the same location, as indicated by the overlap of the two signals in the merged image panel (bottom left). There is also some N-SF-TAP-Rp1
signal in the synaptic region of photoreceptor cells that is not present in wild-type retinas. The N-SF-TAP-Rp1 transgenes in T2 and T3 are over-
expressed relative to the wild-type protein. The over-expressed N-SF-TAP-Rp1 protein localizes correctly to PSC axonemes, but also mis-localizes to
photoreceptor inner segments. The N-SF-TAP-Rp1 signal in the synaptic region is also increased, especially in the line T3 retinas. Note that the outer
nuclear layer is thinner in the line T3 sample, consistent with the photoreceptor degeneration observed in this transgene line. The ONL is also slightly
thinner in the line T2 samples as well. E. Immunofluorescence analyses of wild-type Rp1 protein (anti-Rp1 antibodies; red) and N-LAP-Rp1 protein
(EGFP; green) in three N-LAP-Rp1 transgenic lines and wild-type littermate control. The N-LAP-Rp1 protein in transgene line L1 is located in the
axoneme of PSCs, like the wild-type protein. In addition, there is EGFP signal from N-LAP-Rp1 protein in the inner segments and cell bodies of the
photoreceptors. Since this was not detected by the anti-Rp1 antibodies, it must be due to truncated versions of the N-LAP-Rp1 protein that retain the
N-terminal EGFP tag, but have lost the C-terminal antibody binding domain. The N-LAP-Rp1 transgenes in line L3 is over-expressed relative to the
wild-type protein. The over-expressed N-SF-TAP-Rp1 protein localizes correctly to PSC axonemes, but also mis-localizes to photoreceptor inner
segments and cell bodies. As for the N-SF-TAP-Rp1 line T3, there is photoreceptor degeneration in the L3 line. The N-LAP-Rp1 transgene expression in
line L2 is not completely uniform, with some cells that do not express the transgene evident. In addition, there are red signals in OPL in line L1 and L2,
which could represent the non-specific signaling from the anti-c-Rp1 antibody. It is also possible that this immunoreactivity of Rp1 could correspond
to the C-terminal fragments of Rp1. (IS, inner segment; ONL, outer nuclear layer; OPL, outer plexiform layer; OS, outer segment; 400X magnification
for all images).
doi:10.1371/journal.pone.0043251.g004
Figure 5. Retinal phenotypes of N-SF-TAP-Rp1 and N-LAP-Rp1 transgenic mice. A. Retinal histology from 1-year-old mice of the genotypes
indicated. Note that the retinal structure of the N-SF-TAP-Rp1 line T1 and N-LAP-Rp1 lines L1 and L2 is normal. In contrast, there is photoreceptor
degeneration evident in N-SF-TAP-Rp1 lines T2 and T3, and N-LAP-Rp1 line L3, with loss of photoreceptor nuclei and shortening of photoreceptor
outer segments. (INL, inner nuclear layer; IS, inner segment; ONL, outer nuclear layer; OS, outer segment; 4006magnification for all images). B.
Ultrastructure of photoreceptor sensory cilia in one-year old N-SF-TAP-Rp1 line T1 and N-LAP-Rp1 line L2 mice, compared to that of wild-type
littermate control. Note that the structure of the PSC and organization of the outer segment discs are normal in both transgenic lines, consistent with
the histology shown in A. C. Amplitudes of ERG responses from 1-year-old N-SF-TAP-Rp1 line T1 and N-LAP-Rp1 line L2 mice, compared to that of
wild-type littermate controls. Note that the rod and cone ERG amplitudes are normal in both lines of transgenic mice.
doi:10.1371/journal.pone.0043251.g005
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Figure 6. Expression of the full-length N-SF-TAP-Rp1 and N-LAP-Rp1 proteins prevents photoreceptor degeneration in Rp1Q662X/Q662X
knock-in mice. A. Frozen sections of retina from 2-month-old mice of the genotypes indicated were stained with anti-C-Rp1 antibodies (red). The wild-
type Rp1 protein is located in the axonemes of PSC; full-length Rp1 protein is not detected in the Rp1-Q662X knock-in mice. Full-length Rp1 protein is also
detected in the PSC axonemes of the Rp1-Q662X : N-SF-TAP-Rp1 and Rp1-Q662X : N-LAP-Rp1 mice. There is a mosaic pattern of full-length Rp1 protein
expression in the Rp1-Q662X : N-LAP-Rp1mice. (INL, inner nuclear layer; IS, inner segment; ONL, outer nuclear layer; OS, outer segment; 400Xmagnification
for all images). B. Retinal histology from 2-month-oldmice of the genotypes indicated. The retinal structure of the Rp1-Q662X : N-SF-TAP-Rp1mice is normal,
in contrast to the early photoreceptor degeneration in the Rp1-Q662X mice. There is partial preservation of retina structure in the Rp1-Q662X : N-LAP-Rp1
mice (INL, inner nuclear layer; IS, inner segment; ONL, outer nuclear layer; OS, outer segment; 4006magnification for all images). C. Ultrastructure of PSCs in
two-month old mice of the genotypes indicated. Note that the structure of the PSC and organization of the outer segment discs are normal in the Rp1-
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since these lines express the tagged-Rp1 proteins at relatively
normal levels, and do not exhibit photoreceptor degeneration.
As described above, the Rp1Q662X/Q662X mice do not express full-
length Rp1 protein and experience photoreceptor degeneration,
with decreased retinal function evident as early as 1 month of age.
Addition of the N-SF-TAP-Rp1 and N-LAP-Rp1 wild-type trans-
genes to the Rp1Q662X/Q662X mutant mice resulted in restoration of
expression of full-length Rp1 protein in the retina. As shown in
Figure 6A, the transgenic full-length Rp1 protein was localized
normally to the axonemes of PSCs. There is a mosaic pattern of full-
length Rp1 protein expression in the Rp1Q662X/Q662X : N-LAP-Rp1
mice, which is consistent with the expression pattern of tagged Rp1
in line L2.
The retinal structure was almost completely preserved in the
Rp1Q662X/Q662X : N-SF-TAP-Rp1 mice at 2 months of age. In the
Rp1Q662X/Q662X : N-LAP-Rp1 mice, electron microscopy showed
a mixture of PSCs with normal and aberrant structures
(Figures 4E, 6C). At the age of 12 months, there was notable
photoreceptor degeneration observed in the Rp1Q662X/Q662X
mice, with only a single layer of photoreceptor cells with no
visible outer segments remaining (Figure S1). In contrast, the
photoreceptor cells and organization of outer segments was greatly
preserved in the Rp1Q662X/Q662X : N-SF-TAP-Rp1 mice. In the
Rp1Q662X/Q662X : N-LAP-Rp1 mice, more significant retinal
degeneration was observed, including shorter outer segments with
a mixture of normal discs and disorganized discs (Figure S1). The
phenotype seen in the Rp1Q662X/Q662X : N-LAP-Rp1 mice is
consistent with the mosaic pattern of expression of the N-LAP-Rp1
transgene in the line L2 mice (Figures 4E, 6C). These data also
indicate that Rp1 acts in individual cells in a cell-autonomous
fashion, consistent with its function as a photoreceptor MAP [38].
Consistent with the improved retinal structure, Rp1Q662X/Q662X
: N-SF-TAP-Rp1 mice had significantly improved scotopic and
photopic ERG responses compared to Rp1Q662X/Q662X mice
(Figure 6D). At 2 months of age, the rod a-wave, rod b-wave and
cone b-wave in the Rp1Q662X/Q662X : N-SF-TAP-Rp1 mice
showed no significant difference compared to the wild type
controls. At the age of 12 months, when there were no detectable
ERG responses in the Rp1Q662X/Q662X mice, the maximum
amplitude of the rod a-wave, rod b-wave and cone b-wave were
preserved to 57%, 71% and 90% of normal levels, respectively, in
the Rp1Q662X/Q662X : N-SF-TAP-Rp1 mice; these values were not
statistically different from those observed in the control mice. The
restoration of retinal function in the Rp1Q662X/Q662X : N-LAP-Rp1
mice was not as complete as that in Rp1Q662X/Q662X : N-SF-TAP-
Rp1 mice, presumably because only a portion of the photoreceptor
cells in these mice expressed the N-LAP-Rp1 protein. At 2 month
of age, the maximum amplitude of rod a-wave improved to 50% of
normal, compared to 19% of normal in Rp1Q662X/Q662X mice. At
12 months of age, the maximum amplitude of rod a-wave was
17% of normal in the transgenic mice, which is similar to the level
in 2-month-old knock-in mice.
Discussion
The success of the Phase I clinical trials of gene therapy for LCA
has led to rapid progress in developing genetic therapeutic
strategies. However, efforts to develop gene therapy for dominant
diseases have lagged behind those directed at recessive disease
caused by loss-of-function mutations, in part because of the
assumption that successful treatment of dominant diseases will
require suppression or removal of the protein produced by the
mutant allele [51–54]. Some successes at this suppression or
removal in conjunction with replacement approach have been
reported, yet this approach is clearly more complicated than gene
augmentation therapy and it is only necessary for gain-of-function
mutations [9,10]. Hence, it is critical to distinguish between the
gain-of-function, dominant-negative and haploinsufficiency muta-
tions when gene therapy is applied to dominant diseases. In this
study, we present several important insights into the mechanisms
by which mutations in RP1 cause retinal degeneration. Data from
the family with a frameshift mutation in exon 3 of RP1 confirm
that null alleles of RP1 cause arRP, but haploinsufficiency of RP1
does not cause RP. Data from the Rp1-Q662X knock-in mice
show that mutant alleles with truncating mutations in the final
exon can produce truncated proteins that retain their microtubule
binding domains and localize correctly to the axonemes of PSCs.
Photoreceptor degeneration in the Rp1-Q662X mice can be
delayed or prevented by increasing the ratio of wild-type to mutant
protein without removal of the mutant protein, demonstrating that
the truncated Rp1-Q662X protein expressed in these mutant mice
does not exert a toxic gain-of-function in the retina [9,10]. These
findings are important because they indicate that gene augmen-
tation therapy, such as that used for recently reported LCA clinical
trials, has the potential to be beneficial for both dominant and
recessive RP1 patients. It is also evident that the levels of protein
delivered for therapy will have to be carefully controlled because
over-expression of Rp1 causes retinal degeneration. These results
also raise the question of how many other forms of dominant
retinal disorders have a comparable etiology, and thus could also
be amenable to gene augmentation therapy.
The human genetic study of the family with the p.P229GfsX35
mutation in exon 3 of RP1 provides confirming evidence that
haploinsufficiency of RP1 cannot cause dominant RP. Because the
premature termination codon produced by the resulting frameshift
occurs in exon 3, the transcripts with the identified 1-bp deletion
are expected to be subject to NMD, resulting in no expression of
the mutant RP1 protein [43]. Direct evidence of NMD of this
mutant RP1 allele in the retina cannot be obtained from the
patient; further study using lymphoblasts derived from the patient
and/or an animal models is warranted. The parents and sister of
the affected patient are heterozygous for this frameshift mutation,
but show no evidence of retinal degeneration. This result is
consistent with the recent report by Chen et al, who described a
patient with recessive RP due to two novel frameshift mutations in
RP1, and family member carrying a S2RfsX16 mutation in exon 2
that is unaffected [41]. Together, these findings support the idea
that functional hemizygosity of RP1 does not cause disease.
Q662X : N-SF-TAP-Rp1mice, in contrast to the disorganized PSC observed in the Rp1Q662X/Q662X mice. There is a mixture of cells with normal PSC and cells
with disorganized PSC in the Rp1-Q662X : N-LAP-Rp1 mice (OS, outer segment; RPE, retinal pigment epithelium. Bars =2 mm). D. Amplitudes of ERG
responses from 2month-old and 12-month-oldmice of the genotypes indicated. At 2months not that the rod and cone ERG amplitudes are close to normal
in the Rp1-Q662X : N-SF-TAP-Rp1 mice, in contrast to the reduction of photoreceptor function observed in the Rp1Q662X/Q662X mice. There is partial
restoration of photoreceptor function in the Rp1-Q662X : N-LAP-Rp1 mice. At 12 months photoreceptor function is relatively well preserved in the Rp1-
Q662X : N-SF-TAP-Rp1 mice. There is also some residual photoreceptor function in the Rp1-Q662X : N-LAP-Rp1 mice. Significant differences compared to
controls are indicated by * (P,0.01) and ** (P,0.05).
doi:10.1371/journal.pone.0043251.g006
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The Rp1-Q662X mice provide the first clear demonstration that
mutant Rp1 mRNA with a premature stop codon in the final exon
can escape NMD, and produce truncated protein in photoreceptor
cells in vivo. We have previously generated a gene targeted Rp1-
tm1EAP mouse model that carries an artificial stop codon in last
exon of Rp1 gene [37,47]. In the Rp1-tm1EAP mice, the mutant
Rp1 allele was produced by removing the majority of exon 4, and
thus did not allow for testing the hypothesis that the premature
termination codons in last exon lead to the production of
truncated Rp1 proteins. The Rp1-Q662X allele produces the
same 74 kDa truncated Rp1 protein localized correctly to the
axonemes of PSCs as that produced in the retinas of Rp1-tm1EAP
mice, consistent with retention of the DCX microtubule binding
domains (amino acids 35–236) in the truncated N-terminal Rp1
protein. These results are also consistent with those from PCR of
illegitimate transcripts from lymphoblasts of patients with the
R677X mutation in RP1 [37]. It is hypothesized that in patients
with truncating RP1 mutations in the last exon, the mutant
truncated protein is expressed and retains its ability to binding
axonemal microtubules in the photoreceptor cells.
The Rp1-Q662X mutant allele causes disorganized outer
segment discs, but only when present in the homozygous state in
the study reported here. The lack of phenotype in Rp1+/Q662X
heterozygous mice recapitulates the observation in Rp1-tm1EAP
mice that a single Rp1 mutant allele in Rp1-tm1Eap mice causes
dominant disease only on an congenic albino (A/J) background,
but not on pigmented (mixed 129Sv/C57BL/6J) background [47].
Since the truncated Rp1 proteins produced by the Rp1-tm1EAP
and Rp1-Q662X mouse models are the same, we expect that the
truncated Rp1-Q662X is functional in the retina and a single copy
of Rp1-Q662X would cause dominant disease when it is expressed
on an albino background. Genetic factors are also thought to play
a role in modulating RP1 disease expression in human patients
[26,27,47]. While most truncating mutations in exon 4 of RP1
cause adRP, it has been reported that truncating mutations in RP1
may cause recessive disease in several Indian and Pakistani families
(Figure 1A) [34,40]. We hypothesize that the mode of inheritance
and/or the severity of disease caused by truncating mutation in
RP1 or Rp1 may be controlled is part by genetic background or
modifier genes. Evidence in support of this hypothesis includes the
observation that the truncated protein produced by the Rp1-
tm1EAP mice causes dominant disease on an albino background,
but not pigmented backgrounds. The variation in RP1 disease
severity may also be explained by sequence variants in genes that
encode proteins that interact with RP1, or the level of expression
of the normal allele, and warrants additional investigation [55,56].
Additionally, the stability and localization of different mutant RP1
proteins produced in photoreceptor cells may contribute to
determining the severity of RP1 disease. It has been experimen-
tally demonstrated that the relative degree of protein retention/
degradation and the subcellular localization of mutant proteins
produced by different truncating mutations at a single site in the
ROR2 gene can determine the phenotypic outcome [57].
The data from several lines of Rp1 transgenic mice showed that the
phenotype of the transgenic mice and the location of the protein
expressed by additional transgene are closely correlated to the protein
expression levels in retina. In the N-SF-TAP-Rp1 line T1 and N-LAP-
Rp1 line L2 mice that produce Rp1 proteins in amounts similar to
those produced from a single endogenous Rp1 allele, the tagged Rp1
proteins were located normally in the axonemes of PSCs, and the
retinal structure and function was normal up to at least one year of age
in these transgenic line. This suggests that the epitope tags do not
interfere with Rp1 function and the expression of 50% more Rp1
protein than usual is well-tolerated by photoreceptor cells. The tagged
Rp1 proteins were partially mis-localized to other subcellular locations
when expression of these proteins exceeded normal levels. Over-
expression of Rp1 also resulted in photoreceptor degeneration, as has
been reported for several other photoreceptor proteins, such as
rhodopsin [58,59]. These findings imply that the levels of Rp1 protein
are tightly regulated and thus, the levels of protein delivered for
therapy, such as by gene therapy, will have to be carefully controlled. In
this study, we found that a ratio of 1:2 of wild-type vs. mutant protein is
enough to significantly reduce the retinal degeneration caused by the
truncated Rp1 protein, as evidenced by the relative preservation of
retinal function and structure in the 12-month-old Rp1Q662X/Q662X :
N-SF-TAP-Rp1 mice compared to the Rp1Q662X/Q662X mice. The
level of full-length RP1 protein required to rescue the structure and
function of photoreceptor cells in heterozygous mice or patients will
need to be determined.
It is worth noting that in the N-LAP-Rp1 transgenic mice, EGFP
signal was found separately from Rp1 signal detected by anti-C-
terminal Rp1 antibody (Figure 4). This suggests that the EGFP-
Rp1 fusion protein underwent proteolysis, resulting in separation
of the LAP-tag-containing N-terminal portion of the protein from
the C-terminal portion of the protein to which the antibodies used
are directed [35]. This finding indicates that care is needed
interpreting data obtained using EGFP and other fluorescent
fusion proteins to localize proteins of interest in cultured cells and
in vivo. While it has been suggested by other authors that validation
of fluorescent fusion protein location by detecting the endogenous
protein is important, we have not found other reports of separation
of the EGFP tag from fusion proteins in vivo [60].
In this study, although the Rp1-Q662X mice on a mixed
129Sv/C57BL/6J genetic background are not a model of
dominant disease to test gene therapeutic approaches, the
homozygous Rp1Q662X/Q662X mice provide a valuable model
system to determine if the truncated Q662X protein has a gain-
of-function or a dominant negative effect in photoreceptor cells in
vivo by expressing a wild-type Rp1 allele on this mutant
background. The results from the crossing of Rp1Q662X/Q662X
knock-in mice and Rp1 BAC transgenic mice showed that the
phenotype of the Rp1Q662X/Q662X mice can be rescued without first
removing the mutant protein, indicating that the truncated Rp1
protein does not exert a toxic gain-of-function effect in the
photoreceptor cells in mutant Rp1 animal models.
Based on the findings from human and animal studies, which
rule out haploinsufficiency and gain-of-function as the cause of
RP1 disease, the most logical conclusion would be that truncated
RP1 proteins cause disease via a dominant-negative mechanism
[9,10]. This concept is consistent with the fact that all adRP
mutations are spread over a large protein region in the last exon
and that there are no missense mutations that lead to a very
specific gain-of-function. It is also consistent with the findings that,
in both Rp1-Q662X and Rp1-tm1EAP mouse models, truncated
Rp1 proteins retain their ability to bind to axonemal microtubules
in the photoreceptor cells, but may have lost the ability to interact
with other proteins that are hypothesized to bind to the C-terminal
portion of Rp1 and mediate organization of outer segment discs
along the axoneme [37,38]. It is hypothesized that, in dominant
RP1 disease, the truncated RP1 proteins does not cause disease by
generating a novel toxic function, but rather compete for binding
to axonemal microtubules with full length RP1 protein, and thus
interfering with RP1-mediated organization of outer segment discs
along the axoneme. Additional studies of the genetic mechanism of
and the gene therapeutic approaches for dominant RP1 disease
using Rp1-Q662X or Rp1-tm1EAP mice on an albino background
are warranted to further test this hypothesis.
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The finding that truncating mutations in RP1 does not cause
dominant disease via a gain-of-function mechanism raises the
question of how many other dominant forms of IRD are caused by
a similar mechanism. Despite the great progress made in recent
years discovering novel IRD disease genes, the mechanisms by
which the identified mutations cause disease have only been
evaluated thoroughly in vivo for a limited number of genes [61–63].
An important example of dominant IRD is RP caused by
mutations in the rhodopsin (RHO) gene, which are the most
common cause of adRP [18,64]. It is evident that haploinsuffi-
ciency of RHO does not cause dominant RP, since people
heterozygous for null RHO mutations and heterozygous Rho
knockout mice do not develop retinal degeneration [65]. The most
common mutation adRP mutation in RHO is the P23H mutation,
which accounts for 10 to 15% of adRP in Western populations
[18]. There are conflicting data, however, about whether P23H
mutation in RHO causes adRP via a gain-of-function or dominant-
negative mechanism [66–70]. A recent report that RHO gene
augmentation therapy preserves retinal function in P23H RHO
transgenic mice is consistent with a dominant-negative effect of the
P23H mutation [71]. It is possible, therefore, that the P23H
mutation in RHO, and other dominant mutations in RHO and
other IRD disease genes cause disease via dominant-negative
mechanisms, and thus like dominant RP1 disease may also be
amendable to gene augmentation therapy.
Materials and Methods
Clinical Evaluations
The clinical study was approved by the ethical review board of
The Rotterdam Eye Hospital and conformed to the tenets of the
Declaration of Helsinki. Written consent was given by the
participants for their information to be stored in the hospital
database and used for research. Retrospective data of the index
patient were evaluated. Ophthalmic examination of all family
members included best-corrected visual acuity (Snellen), slitlamp
examination, and fundoscopy. Fundus autofluorescense images
(30o, alignment of 15 frames) were obtained with a confocal
scanning laser ophthalmoscope with 488 nm excitation (Spectral-
isH, Heidelberg Engineering, Heidelberg, Germany). Electroreti-
nograms (according to ISCEV standards) were performed in the
index patient and his parents [72]. Fundus photographs were
obtained in the index patient and his father.
Genome-wide Homozygosity Mapping
In a large study aiming at the identification of the genetic causes
of RP in The Netherlands via homozygosity mapping [42], 231
Dutch arRP patients were genotyped on a high-resolution
Genome-wide Human SNP array 5.0 that contains 500,000 SNPs
and 420,000 non-polymorphic probes for copy number detection
(Affymetrix, Santa Clara, CA, USA). Homozygous regions in the
patients’ genome were calculated using Partek Genomics Suite
software (Partek, St. Louis, MO, USA). Stretches of DNA that
contained 250 or more homozygous SNPs (1.5 Mb on average)
were considered to be significant homozygous regions.
RP1 Sequence Analysis
Patients that were homozygous for the genomic region
containing the RP1 gene were selected for sequence analysis.
Primers to amplify all exons and intron-exon boundaries of RP1
are available on request. PCR products were sequenced with the
ABI PRISM Big Dye Terminator Cycle Sequencing V2.0 Ready
Reaction kit and the ABI PRISM 3730 DNA analyzer (Applied
Biosystems, Foster City, CA, USA).
Generation of Rp1Q662X/Q662X Knock-in Mice
This research followed the tenets of the ARVO Statement for the
Use of Animals in Ophthalmic and Vision Research, and the
guidelines of the Massachusetts Eye and Ear Infirmary for Animal
Care and Use, and was specifically approved by Institutional
Animal Care and Use Committees at the Massachusetts Eye and
Ear Infirmary. The Rp1-Q662X targeting vector was generated
from a mouse bacterial artificial chromosome (BAC) clone that
contains the entire mouse Rp1 gene using modified recombineering
techniques (Fig. 2A). This BAC clone (314) was identified by
screening high-density filters from the RPCI-22 (129S6/SvEvTac)
Mouse BAC Library (BACPAC web site: http://www.chori.org/
bacpac/libraryres.htm/provided in the public domain by the
National Center of Excellence in Genomics at Children’s Hospital
Oakland Research Center, Oakland, CA). Briefly, the neomycin-
zeocin resistance cassette from plasmid pKOEZ59 was inserted
between exons 3 and 4 of the Rp1 gene in BAC 314 using
recombination-based techniques [45,73]. A 23.8 kb portion DNA
containing the modified Rp1 gene was then retrieved into pBlue-
script II via homologous recombination, to create wild type
construct [74]. This vector was mutagenized to introduce the
Q662Xmutation and then linearized to transfect into AB2.2 mouse
ES cells (obtained from Dr. Allan Bradley at the Wellcome Trust
Sanger Institute, UK website: http://www.sanger.ac.uk/resources/
mouse/micer/) [75]. Approximately 250 G418 resistant colonies
were selected and expanded according to established techniques
[50]. DNA prepared from the isolated clones was digested with
BamHI and analyzed by Southern blot using a 59 probe to identify
correctly targeted ES cells. DNA from the single positive
recombinant was also digested with PmeI, and analyzed by Southern
blot using a 39 probe. Probes for Southern blot analysis were
amplified from BAC 314A DNA, and cloned into the pCRII-
TOPO vector (Invitrogen, Carlsbad, CA). The 59 probe was
amplified with primers 59-CAAGAATCTGGCGGCCGCTG-
GACTGAATGTCAC-39, and 59- GAGAATAGGAACTTC-
GATCCATAACTTCGTATAATG-39, and the 39 probe with
primers 59-GAATCCAGGTGGGGAAGAGCACGGGTAA-39
and 59-TATTTTATCTAAAAGACCTATCTCGAATCC-39
(Figure 2B).
One ES cell clone with the Rp1-Q662X-Neo allele was injected
into blastocysts to generate chimeric mice [50]. Chimeric mice
were generated using standard techniques, and the Frt-flanked
neomycin selection cassette was removed by crossing the Rp1-Neo-
Q662X mice with universal FLPe deleter mice [46]. The final
excised targeted Rp1-Q662X knock-in allele was verified by PCR
and sequencing (Figure 2C). Heterozygous and homozygous
animal were generated by intercrossing the F1 progeny. Geno-
typing was performed by PCR analysis of tail DNA using primers:
59-TACTGTTTTTCCTTGGCTTACTC-39 and 59-ACTTTG-
GCTGTTGTGTTTCTTA-39. The sizes of the PCR products
amplified from wild-type and mutant Rp1 alleles are 231 bp and
497 bp, respectively (Figure 2D).
Generation of Rp1 BAC Transgenic Mice
To attempt to fully recapitulate Rp1 expression with a
transgene, we used a BAC genomic clone containing a 140 kb
fragment of mouse genomic DNA to produce the transgenic mice.
This 140 kb fragment encompassed the complete Rp1 gene and, in
addition, contained 53 kb of 5-flanking DNA and 62 kb of 3-
flanking DNA (Fig. 4). The transgenic construct was produced by
incorporating two different tags, SF-TAP (Strep-tag II-FLAG) and
LAP (EGFP-S-tag) into the N-terminus of the Rp1 coding
sequence in exon 2 of the Rp1 gene in the BAC (Fig. 4A)
[48,49]. Three lines of N-SF-TAP-Rp1 transgenic mice (designated
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T1–T3) and three lines of N-LAP-Rp1 transgenic mice (designated
L1–L3) were produced following microinjection of each BAC into
oocytes [50]. The Rp1 transgenes present in the Rp1 transgenic
lines were distinguished from the endogenous Rp1 locus by PCR
amplification with TAP-specific primers 59-CATTGTTT-
GAGTGTAAATATCCGCATTGG-39, 59-CGCTTCCTCCT-
CCCTTCTCGAACTGAG-39 and LAP-specific primers 59-
TCGCCGGACACGCTGAACTTGTG-39, and 59-CATTG-
TTTGAGTGTAAATATCCGCATTGG-39. Transgenic proge-
ny were backcrossed to C57BL/6J mice to establish lines from
each founder. In the present study, transgenic line T1 and L2 were
used for crosses with Rp1-Q662X knock-in mice. All progeny were
then genotyped for the presence of the Rp1 transgene and for the
presence of the mutant Q662X allele.
Electroretinography
Electroretinography (ERG) testing in the mice was performed as
previously described [37]. In brief, the pupils of dark-adapted,
anesthetized mice were dilated with 1% tropicamide and the mice
were placed on a stage maintained at 37uC. Retinal responses
were detected with platinum electrodes placed in contact with the
corneas. A platinum wire loop placed in the mouth served as the
reference and a ground electrode. ERG were recorded with
Espion Electrophysiology System (Diagnosys LLC, Lowell, MA)
calibrated by the vendor. A stage with the mouse was positioned in
such a way that the mouse head was located inside the ColorDome
stimulator thus ensuring full-field uniform illumination. All
manipulations were performed under dim red light, and after
being placed into the ColorDome the animal was left in darkness
for 10 min for complete dark re-adaptation. The ERG recordings
followed in general guidelines recommended by the ‘‘Standard for
Clinical Electroretinography’’ [76]. The rod b-wave (‘‘weak flash
rod response’’ by the Standard) was recorded at a response to
green (l=513 nm) flash intensity of 1.0861022 scot cd s m22.
The saturating rod a-wave was elicited by a white flash of 500 scot
cd s ? m22 intensity produced by a xenon lamp (‘‘High-intensity
ERG’’ by the Standard). The single cone ERG was elicited by a
500 scot cd s ? m22 intensity white flash delivered on a 30 scot cd ?
m22 background suppressing the rod activity. The ERGs were
recorded in a 0.1 to 300 Hz bandwidth, digitized at 1 kHz, and
the amplitudes of the respective responses were measured from the
baseline to peak for the a-wave, and from the trough to peak for
the rod and cone b-waves. Each trace is the average of 3 to 10
individual records (the traces of the two eyes were also averaged
during analysis). Statistical analysis was performed using Prism
v3.02 software (GraphPad, San Diego, CA).
RT-PCR
Retinas from animals of different genotypes at the desired ages
were collected and homogenized in Trizol (Invitrogen, Carlsbad,
CA). Total RNA was extracted from one retina and reverse
transcribed using Superscript II (Invitrogen). The PCR reactions
were then performed using 2 mL of first-strand cDNA to amplify
the region of RP1 transcript containing exon 2 to 3 and exon 3 to
4. The primer sets used were: forward, 59-TCGGCCCTGG-
CTGAGTAGTCG-39 (on exon 2), reverse, 59-TTCCTG-
GTTTAAATGGCTCCCTTCC-39 (on exon 3); and forward,
59-TGCCAAGTTACCAGGAATCTC-39 (on exon 3), reverse,
59-CGACCGTCATCGTACCATCTTG-39 (on exon 4).
Western Blotting
Retinas from animals of different genotypes at the desired ages
were collected and homogenized in sample buffer (NuPAGE;
Invitrogen). Solubilized retinal protein samples were then processed
for Western blot analysis as described [35]. Briefly, equivalent
amounts of protein from each genotype were separated on 4% to
12% Tris-acetate gel (NuPage; Invitrogen) and transferred to
polyvinylidene difluoride (PVDF) membrane (Millipore, Bedford,
MA). The membranes were blocked with 10% nonfat dry milk in
TBS-T and incubated with primary antibodies. Chicken polyclonal
anti-C-Rp1 antibody and anti-N-Rp1 antibodies were used to
detect the normal full length Rp1 and the mutant truncated Rp1
protein. Monoclonal anti-alpha 1 Sodium Potassium ATPase
antibody from Abcam (Cat. ab7671) antibody was used as internal
control to quantify the expression level of transgenic Rp1 protein.
Antibody binding was detected with alkaline phosphatase conju-
gated or Odyssey IRDye secondary antibodies. Positive signals were
visualized and quantified by Odyssey Infrared Imaging System (Li-
Cor Biosciences, Lincoln, NE).
Immunofluorescence, Light and Electron Microscopy
Eyes from Rp1-Q662X knock-in mice and transgenic mice were
processed for immunostaining experiments as described previously
[37]. Ten micron cryosections were cut and evaluated using anti-N-
Rp1 and anti-C-Rp1 and anti-flag (Sigma, St. Louis, MO)
antibodies. Sections were incubated overnight at 4uC with primary
antibodies followed by Alexa 488- and Alexa 555-conjugated
secondary antibodies (Invitrogen). Stained sections were viewed
with a Zeiss LSM 510 Meta confocal microscope, and the images
were processed with Zeiss Meta 510 software. Preparation of retinas
for light and electron microscopy was performed as previously
described [37,38]. Semithin (0.75 mm) sections were cut and stained
with alkaline toluidine blue for light microscopy, and 60- to 80-nM
ultrathin sections were stained with 2% uranyl acetate and lead
citrate, and photographed using a transmission electron microscope.
Supporting Information
Figure S1 Expression of the full-length N-SF-TAP-Rp1
and N-LAP-Rp1 proteins prevents photoreceptor degen-
eration in Rp1Q662X/Q662X knockin mice. A. Retinal
histology from 12-month-old mice of the genotypes indicated.
The retinal structure of the combined Rp1-Q662X : N-SF-TAP-Rp1
mice is essentially normal, in contrast to the early photoreceptor
degeneration in the Rp1-Q662X mice. There is partial preservation
of retina structure in the combined Rp1-Q662X : N-LAP-Rp1 mice
(INL, inner nuclear layer; IS, inner segment; ONL, outer nuclear
layer; OS, outer segment; 4006magnification for all images). B.
Ultrastructure of PSCs in 12-month old mice of the genotypes
indicated. Note that the structure of the PSC and organization of
the outer segment discs are normal in the combined Rp1-Q662X :
N-SF-TAP-Rp1 mice, in contrast to the grossly disorganized PSC
observed in the Rp1Q662X/Q662X mice. More significant disorgani-
zation of PSCs was observed in the combined Rp1-Q662X : N-LAP-
Rp1 mice, including shorter outer segments with a mixture of
normal discs and disorganized discs (OS, outer segment; RPE,
retinal pigment epithelium. Bars = 2 mm).
(TIF)
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